OnKure Q3 net loss $14.7M; cash $70.3M; initial data from PI3K trial pushed to Q1 2026

OnKure Therapeutics, Inc.

2025-Q3 EPS reported -$3.41

Cash $70.3M as of Sept 30, 2025; expected to fund operations into Q4 2026.
Net loss $14.7M ($1.09/share) vs $11.6M loss in Q3 2024.
First patients dosed in two triplet arms of PIKture-01: fulvestrant+ribociclib and trastuzumab+tucatinib.
Initial clinical data from monotherapy and fulvestrant arms now expected Q1 2026.
Next-gen PI3Kα pan-mutant inhibitor candidate selection announced; more details Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.